Dr. Ruan on the Incidence of MCL

Partner | Cancer Centers | <b>Weill Cornell Sandra & Edward Meyer Cancer Center</b>

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the incidence of mantle cell lymphoma (MCL).

MCL is a rare subtype of B-cell non-Hodgkin lymphoma (NHL), says Ruan. In North America, MCL occurs in approximately 5% to 6% of new patients diagnosed with NHL.

Moreover, the disease tends to affect older patients, Ruan explains. The median age of patients who receive a diagnosis of MCL is 65 years.

Within the past decade, the MCL paradigm has expanded to include multiple new treatment options, Ruan says. These therapies have greatly improved survival for patients in this population.

Despite these advances, patients with MCL remain in need of additional therapies to further prolong survival, concludes Ruan.